Evidence map›Paper›PMID 34070628›Full record

ReviewJournal of clinical medicine2021

Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.

Giuseppe Carota, Simone Ronsisvalle, Federica Panarello, Daniele Tibullo, Anna Nicolosi, Giovanni Li Volti

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Iron and iron-related proteins in COVID-19.Clinical and experimental medicine · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Major trace elements and their binding proteins in the early phase of Covid-19 infection.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2022
    Article
  11. Review
  12. Multifaceted Roles of Ferroptosis in Lung Diseases.Frontiers in molecular biosciences · 2022
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giuseppe CarotaSection of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-9618-3563
Simone RonsisvalleDepartment of Drug Sciences, University of Catania, 95123 Catania, Italy.
Federica PanarelloDepartment of Drug Sciences, University of Catania, 95123 Catania, Italy.
Daniele TibulloSection of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-4416-8556
Anna NicolosiHospital Pharmacy Unit, Ospedale Cannizzaro, 95125 Catania, Italy.
Giovanni Li VoltiSection of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-8678-2183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the epidemic caused by SARS-CoV-2 callings for international attention to develop new effective therapeutics, no specific protocol is yet available, leaving patients to rely on general and supportive therapies. A range of respiratory diseases, including pulmonary fibrosis, have been associated with higher iron levels that may promote the course of viral infection. Recent studies have demonstrated that some natural components could act as the first barrier against viral injury by affecting iron metabolism. Moreover, a few recent studies have proposed the combination of protease inhibitors for therapeutic use against SARS-CoV-2 infection, highlighting the role of viral protease in virus infectivity. In this regard, this review focuses on the analysis, through literature and docking studies, of a number of natural products able to counteract SARS-CoV-2 infection, acting both as iron chelators and protease inhibitors.

Indexed as

COVID-19iron chelationnatural productsprotease inhibitionSARS-Cov-2

Identifiers

PMID34070628
PMCPMC8198259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.